Going Beyond EXTREME in Head and Neck Cancer

Access Course


Going Beyond EXTREME in Head and Neck CancerExperts discuss the emergence of checkpoint inhibition in the first-line treatment of SCCHN as well as its ongoing role in second-line treatment.



This activity is intended for oncologists, surgeons, and pathologists.



The goal of this activity is to discuss the evolving role of immunotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).



Approximate Time to Complete: 30 minutes



Credit Available: Mar. 26, 2019 - Mar. 26, 2020



Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the emerging clinical data on the use of cancer immunotherapies in the management of SCCHN
  • Have greater competence related to Selection of regimens for patients with SCCHN
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50